MRK (MRK) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving MRK (MRK) right now is Keytruda's remaining runway is substantial: Keytruda recorded roughly $31.7 billion in sales in 2025, up 7 percent year over year, and management projects peak sales near $35 billion by 2028. Revenue (FY 2025) is ~$65.0 billion. If that keeps playing out, the setup is favourable; the risk to it is the central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S. No one can predict where MRK trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive MRK (MRK) higher?
Keytruda's remaining runway is substantial
Keytruda recorded roughly $31.7 billion in sales in 2025, up 7 percent year over year, and management projects peak sales near $35 billion by 2028. The FDA-approved subcutaneous formulation, Keytruda Qlex, was cleared in September 2025 and offers a more convenient dosing route that could retain patient loyalty even after intravenous biosimilars enter the market, effectively extending the commercial franchise beyond 2030 in some patient segments.
A tripling of the Phase III pipeline provides post-cliff optionality
Merck's late-stage pipeline has nearly tripled since 2021, now encompassing more than 50 active clinical programs with over 30 in Phase 3. Management has outlined a potential $70 billion in non-risk-adjusted commercial opportunities from the current pipeline by the mid-2030s, anchored by new oncology combinations, Winrevair's expansion into heart failure indications, and MK-0616, an oral PCSK9 inhibitor with potential to reach a broad cholesterol treatment population.
Newer commercial launches are already generating revenue
Winrevair, approved for pulmonary arterial hypertension, reached $1.4 billion in sales in its first full year of commercialization in 2025. Capvaxive, Merck's 21-valent pneumococcal vaccine, recorded $759 million in 2025 sales and carries blockbuster potential as it competes for adult immunization share. These products demonstrate that Merck's diversification beyond Keytruda is moving from pipeline aspiration to commercial reality.
Cost discipline and cash generation support the transition
Merck is executing a $3 billion cost-reduction program targeting completion by end of 2027, with savings fully reinvested to support new launches and R&D. The company reported a gross margin near 75 percent in fiscal year 2025 and net income of approximately $18.3 billion on revenues of $65 billion, providing substantial free cash flow to fund M&A, dividends, and capital investment in U.S. manufacturing capacity.
What could weigh on MRK?
The central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S. patents expire in late 2028, at which point biosimilars from companies including Celltrion and Samsung Bioepis are positioned to enter and compress pricing. This cliff is compounded by IRA Medicare price cuts already reducing Januvia reimbursement by 79 percent starting in 2026, creating a multi-billion-dollar annual headwind from drug pricing reform. Gardasil faces its own pressure from weak China demand and a CDC recommendation change that reduces the number of doses in the pediatric schedule, and near-term earnings growth is constrained by acquisition-related charges and tariff costs estimated at $200 million annually at current levels. The timing gap between Keytruda's revenue decline and the pipeline's commercial maturity, expected around the mid-2030s, is the key uncertainty investors must weigh.
How to think about a MRK forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the MRK guide and whether MRK is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the MRK outlook
The bottom line: what is driving MRK (MRK) is Keytruda's remaining runway is substantial, with revenue (fy 2025) at ~$65.0 billion. If that keeps playing out the setup is favourable; the risk is the central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S. No one can predict the price, so treat any MRK forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around MRK with Walnut
Use MRK as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for MRK (MRK)?
+
No one can reliably predict where MRK will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push MRK higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive MRK higher?
+
The main growth drivers are Keytruda's remaining runway is substantial; A tripling of the Phase III pipeline provides post-cliff optionality; Newer commercial launches are already generating revenue. Whether they play out is the real question, not a guaranteed path.
What are the risks to MRK?
+
The central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S. patents expire in late 2028, at which point biosimilars from companies including Celltrion and Samsung Bioepis are positioned to enter and compress pricing. This cliff is compounded by IRA Medicare price cuts already reducing Januvia reimbursement by 79 percent starting in 2026, creating a multi-billion-dollar annual headwind from drug pricing reform. Gardasil faces its own pressure from weak China demand and a CDC recommendation change that reduces the number of doses in the pediatric schedule, and near-term earnings growth is constrained by acquisition-related charges and tariff costs estimated at $200 million annually at current levels. The timing gap between Keytruda's revenue decline and the pipeline's commercial maturity, expected around the mid-2030s, is the key uncertainty investors must weigh.
Will MRK stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. MRK's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is MRK a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the MRK "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.